Evidence mapPaperPMID 42418005Full record

ReviewZeitschrift fur Gerontologie und Geriatrie2026

[Anabolic treatment in geriatric patients with osteoporosis].

Judith Haschka

Abstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Gerontologie und Geriatrie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Judith HaschkaHanusch Krankenhaus, 1. Medizinische Abteilung, Ludwig Boltzmann Institut für Osteologie, Heinrich-Collin-Str. 30, 1140, Wien, Österreich. Judith.haschka@lbg.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporotic fractures are a major cause of morbidity, functional decline, and mortality in older adults. Despite effective treatment options, a substantial treatment gap persists in primary and secondary fracture prevention. Osteoanabolic agents stimulate bone formation and lead to a rapid improvement in bone mineral density and bone microarchitecture. Clinical trials demonstrate superiority over antiresorptive therapies in patients at very high or imminent risk of fracture; however, treatment in geriatric populations requires a differentiated balancing of the benefit-risk ratio with careful consideration of comorbidities, administration feasibility and cardiovascular safety. This CME article provides a clinically oriented overview of mechanisms of action, efficacy, safety and practical decision strategies for osteoanabolic treatment in older individuals.

Indexed as

Antibodies, MonoclonalBone Density Conservation AgentsOsteoporosisOsteoporotic FracturesParathyroid Hormone-Related ProteinAgedAged, 80 and overEvidence-Based MedicineFemaleHumansMaleTeriparatideTreatment OutcomeabaloparatideAntibodies, MonoclonalBone Density Conservation AgentsParathyroid Hormone-Related ProteinromosozumabTeriparatideAbaloparatideBone metabolismFracture riskRomosozumabTeriparatide

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.